Metabolic dysfunction, antidiabetic drugs, and asthma: bibliometric evidence, emerging trends, and translational frontiers from 2006 to 2025.

Jiang R, Wang J, Wang S

Open source

DOI
10.3389/fendo.2026.1883559
Published
2026
Container
Frontiers in endocrinology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fendo.2026.1883559,
  title = {Metabolic dysfunction, antidiabetic drugs, and asthma: bibliometric evidence, emerging trends, and translational frontiers from 2006 to 2025.},
  author = {Jiang R and Wang J and Wang S},
  year = {2026},
  journal = {Frontiers in endocrinology},
  doi = {10.3389/fendo.2026.1883559},
  url = {https://doi.org/10.3389/fendo.2026.1883559}
}

RIS

TY  - JOUR
TI  - Metabolic dysfunction, antidiabetic drugs, and asthma: bibliometric evidence, emerging trends, and translational frontiers from 2006 to 2025.
AU  - Jiang R
AU  - Wang J
AU  - Wang S
PY  - 2026
JO  - Frontiers in endocrinology
DO  - 10.3389/fendo.2026.1883559
UR  - https://doi.org/10.3389/fendo.2026.1883559
ER  - 

APA

R, J., J, W., & S, W. (2026). Metabolic dysfunction, antidiabetic drugs, and asthma: bibliometric evidence, emerging trends, and translational frontiers from 2006 to 2025.. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2026.1883559

Source records